Evidence map›Paper›PMID 22488635›Full record

ArticleDigestive diseases and sciences2012

Effect of the expression of matrix metalloproteases and their tissue inhibitors on survival of patients with resectable colorectal cancer.

Lucía González, Noemí Eiró, Luis O González, Alejandro Andicoechea, Esther Barbón, José L García-Muñiz, Francisco J Vizoso

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lucía GonzálezUnidad de Investigación, Hospital de Jove, Avda. Eduardo Castro s/n, 33920 Gijón, Asturias, Spain.
Noemí Eiró
Luis O González
Alejandro Andicoechea
Esther Barbón
José L García-Muñiz
Francisco J Vizoso
Fundación Hospital de Jove · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMatrix metalloproteases (MMPs) and their tissue inhibitors (TIMPs) are of crucial importance in the degradation of the stromal connective tissue and basement membrane components. Study of the behavior of these components might help to predict the aggressiveness of tumors.

aimsTo evaluate the expression and clinical relevance of MMPs and TIMPs for patients with resectable colorectal carcinoma.

methodsAn immunohistochemical study was performed using tissue arrays and specific antibodies against MMPs-1, 2, 7, 9, 11, 13, and 14, and TIMPs-1, 2 and 3. Determinations were performed in cancer specimens from 104 patients with resectable colorectal cancer. The minimum period of follow-up was 12.5 years for patients without recurrence. To identify specific groups of tumors with distinct expression profiles, the data were analyzed by unsupervised hierarchical cluster analysis.

resultsExpression of MMP-11 by fibroblasts and MMP-13 by tumor cells were associated with poor prognosis. The dendrogram revealed first-order division of tumors into two distinct MMP/TIMP molecular profiles, designated group 1 (n = 50) and group 2 (n = 54). Group 2 was characterized by significantly higher expression of MMP-1, 11, and 13, and TIMP-3.

conclusionOur results emphasize the prognostic value of MMP-11 and 13 expression in colorectal cancer.

Indexed as

AgedBiomarkers, TumorCarcinomaColorectal NeoplasmsFemaleHumansMaleMatrix MetalloproteinasesMiddle AgedSpainTissue Inhibitor of MetalloproteinasesBiomarkers, TumorMatrix MetalloproteinasesTissue Inhibitor of Metalloproteinases

Identifiers

PMID22488635
OpenAlexW2049270465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.